⌘K
Loading ticker…
Fate Therapeutics, Inc. · Healthcare · Pharmaceutical Products
As of 2026-06-26, Fate Therapeutics, Inc. (FATE) has a 3-month relative strength percentile of 93 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 76. The current market Stance is 47 (Neutral). Sector: Healthcare. Average daily range 11.2%, relative volume 3.67×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
3m RS is 93, Market Stance is mixed at 47, A/D rating B
YoY sales growth, last 8 quarters. Sales must back the earnings story.
TTM operating margin. Expansion = real operating leverage.
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
Daily range, ATR, beta, and the math for a 1-ADR stop.
FATE is in a stage 2 uptrend, week 1. Extended from base. VCP detected: inconclusive. Distance from 50d / 200d: 8.1% / 52.3%.
Strong relative strength, but attention is quiet relative to this name’s own recent norm. Academic work links low public attention to better forward returns on average — context to weigh, not a forecast.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
News
Related searches
FATE is held by 3 ETFs as of Mar 2026. Top owner: VTI at 0.00% weight, $4M notional. Top 3 carry $8M.
Top 3 by value, from SEC N-PORT-P filings dated Mar 2026.
| ETF | Weight | Value |
|---|---|---|
| VTIVanguard Total Stock Market ETF | 0.00% | $4M |
| IWMiShares Russell 2000 ETF | 0.00% | $3M |
| VXFVanguard Extended Market ETF | 0.00% | $1M |
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | FATE Jan avg: 5.92% median: -0.05% win: 50% σ: 46.97% n: 4 2022-04-12 → 2026-05-29 | FATE Feb avg: 7.08% median: 8.89% win: 75% σ: 16.54% n: 4 2022-04-12 → 2026-05-29 | FATE Mar avg: -12.93% median: -12.89% win: 25% σ: 14.34% n: 4 2022-04-12 → 2026-05-29 | FATE Apr avg: 1.24% median: 4.17% win: 60% σ: 40.13% n: 5 2022-04-12 → 2026-05-29 | FATE May avg: 15.79% median: -6.83% win: 20% σ: 62.56% n: 5 2022-04-12 → 2026-05-29 | FATE Jun avg: -4.19% median: -6.59% win: 25% σ: 7.94% n: 4 2022-04-12 → 2026-05-29 (current) | FATE Jul avg: 17.67% median: 10.71% win: 50% σ: 33.54% n: 4 2022-04-12 → 2026-05-29 | FATE Aug avg: -22.55% median: -22.76% win: 0% σ: 15.39% n: 4 2022-04-12 → 2026-05-29 | FATE Sep avg: -3.32% median: -9.45% win: 25% σ: 17.03% n: 4 2022-04-12 → 2026-05-29 | FATE Oct avg: -11.60% median: -10.64% win: 25% σ: 16.46% n: 4 2022-04-12 → 2026-05-29 | FATE Nov avg: 13.82% median: 16.64% win: 50% σ: 26.00% n: 4 2022-04-12 → 2026-05-29 | FATE Dec avg: -15.77% median: -30.88% win: 25% σ: 47.16% n: 4 2022-04-12 → 2026-05-29 |